# Are We Over-Diagnosing Cannabis Use Disorder in Prescribed Medical Cannabis Patients? > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/prescription-cannabis-use-disorder-dsm5-study/ > **Published:** 2026-08-05T18:01:15-04:00 | **Last Modified / Clinically Audited:** 2026-09-27T22:01:18-04:00 > **Clinical Summary:** prescription cannabis use disorder: A new Addiction journal study finds standard DSM-5 criteria may overstate Cannabis Use Disorder in patients using medical... ---   CED Clinical Relevance #80 High Clinical Practice Relevance A peer-reviewed August 2, 2026 study in Addiction directly tests whether standard DSM-5 [Cannabis Use Disorder](https://cedclinic.com/sex-differences-cannabis-stress-reactivity-oxytocin/) criteria over-classify patients who use prescribed [medical cannabis](https://cedclinic.com/therapeutic-benefits-of-thc/) exactly as directed, with direct implications for how prescribers diagnose and counsel patients. Clinical Insight | CED Clinic A secondary analysis of the CAMS22 survey compared two ways of diagnosing [Cannabis Use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/) Disorder in 2,054 Australian adults prescribed [medical cannabis](https://cedclinic.com/therapeutic-benefits-of-thc/). Using the standard 11-item DSM-5 criteria for everyone, 36.4 percent met any [Cannabis Use Disorder](https://cedclinic.com/sex-differences-cannabis-stress-reactivity-oxytocin/) threshold. Applying a 9-item Prescription [Cannabis Use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/) Disorder framework, which removes tolerance and withdrawal criteria for the 986 patients using cannabis strictly as prescribed, that figure dropped to 31.2 percent overall, and [Cannabis Use Disorder prevalence](https://cedclinic.com/cannabis-use-insomnia-patients-sleep-benefits/) within the as-prescribed subgroup fell from 20 percent to 9 percent. The authors argue tolerance and withdrawal are expected pharmacological effects of following a prescription, not evidence of a substance use disorder, and that applying illicit-use diagnostic criteria to appropriately prescribed patients may inflate apparent disorder rates. Cannabis Use DisorderDSM-5Medical Cannabis Prescribing[Addiction Medicine](https://cedclinic.com/cognitive-flexibility-alcohol-cocaine-misuse-effects/)Diagnostic Criteria Audience Medical cannabis patients, prescribing clinicians, [addiction medicine](https://cedclinic.com/cognitive-flexibility-alcohol-cocaine-misuse-effects/) specialists, and policymakers shaping cannabis use disorder diagnostic standards Primary Topic whether standard DSM-5 Cannabis Use Disorder criteria appropriately classify patients using medical cannabis exactly as prescribed Source [Read the full source   ](https://pubmed.ncbi.nlm.nih.gov/42543176/)| **[More access here](https://cedclinic.com/)** A new Addiction journal study of 2,054 Australians prescribed medical cannabis found that removing tolerance and withdrawal from Cannabis Use Disorder criteria, which are expected effects of following a prescription, cut apparent disorder rates among as-prescribed users by more than half. The findings raise questions about whether current diagnostic tools fit prescribed medical cannabis populations. What This Study Teaches Us Standard substance use disorder criteria built for illicit use may not translate cleanly to prescribed medical cannabis, because tolerance and withdrawal can reflect expected pharmacology rather than loss of control. Why This Matters Clinicians who prescribe or manage medical cannabis patients routinely face questions about dependence and misuse. If standard DSM-5 criteria systematically overstate Cannabis Use Disorder in patients using cannabis exactly as directed, that has direct implications for diagnosis, documentation, insurance and employment consequences, and how prescribers counsel patients about what tolerance and physical dependence do and do not mean. Study Snapshot Study Type Secondary analysis of a cross-sectional consumer survey (CAMS22) Sample 2,054 Australian adults who used prescribed medical cannabis in the past 12 months As-Prescribed Subgroup 986 participants (48%) reporting cannabis use only as prescribed Diagnostic Frameworks Compared Standard 11-item DSM-5 CUD vs. proposed 9-item Prescription CUD (excludes tolerance and withdrawal) Any CUD, Full Sample 36.4% (11-item) vs 31.2% (mixed Pr-CUD/CUD framework) Any CUD, As-Prescribed Subgroup 20% (11-item) vs 9% (9-item Pr-CUD); absolute difference 11.8 points (95% CI 8.3-15.8) Moderate-Severe CUD, As-Prescribed Subgroup 5% (11-item) vs 2% (9-item Pr-CUD); absolute difference 2.9 points (95% CI 1.4-5.0) Published August 2, 2026 Journal Addiction PMID 42543176 DOI 10.1111/add.70559 Clinical Bottom Line In this Australian survey, using a diagnostic framework that excludes tolerance and withdrawal cut apparent Cannabis Use Disorder rates roughly in half among patients using medical cannabis exactly as prescribed. That does not mean prescribed medical cannabis carries no risk of problematic use, but it suggests standard illicit-use criteria may overstate disorder rates in appropriately prescribed patients. What the Study Compared Researchers used data from the CAMS22 survey, an anonymous online cross-sectional survey of Australian adults who reported medical cannabis use in the past year, and applied two different diagnostic frameworks to the same respondents. The standard approach used all 11 DSM-5 Cannabis Use Disorder criteria for every participant. The alternative Prescription Cannabis Use Disorder framework used only 9 criteria, excluding tolerance and withdrawal, for the 986 participants who reported using cannabis strictly as prescribed. What the Numbers Showed Among the 986 patients using cannabis only as prescribed, standard DSM-5 criteria classified 20 percent as meeting any Cannabis Use Disorder threshold. The prescription-aware framework classified only 9 percent, an absolute reduction of 11.8 percentage points (95% CI 8.3 to 15.8; odds ratio 1.3, 95% CI 1.1 to 1.4). For moderate-to-severe Cannabis Use Disorder, the same subgroup dropped from 5 percent under standard criteria to 2 percent under the prescription-aware framework (absolute reduction 2.9 percentage points, 95% CI 1.4 to 5.0; odds ratio 2.6, 95% CI 1.6 to 4.4). Why This Matters for Diagnosis Tolerance and withdrawal are pharmacologically expected with many prescribed medications, including opioids and benzodiazepines, and are not by themselves evidence of a substance use disorder when a patient is following a prescription. The authors argue that applying diagnostic criteria designed for illicit cannabis use to appropriately prescribed patients may inflate apparent disorder prevalence, with downstream consequences for clinical labeling, insurance, employment, and legal proceedings. How Strong Is This Evidence? This is a reasonably large sample (2,054 respondents; 986 in the as-prescribed subgroup) with a purpose-built comparison of two diagnostic frameworks applied to the same population, which lets the authors isolate the specific effect of removing tolerance and withdrawal criteria. The study was published in Addiction, a peer-reviewed addiction medicine journal. Where This Paper Deserves Skepticism This is a secondary analysis of a single cross-sectional, self-reported, anonymous online survey conducted in Australia, which limits causal inference and generalizability to other prescribing systems, including the United States. Self-report cannot be independently verified against pharmacy or prescriber records, and using cannabis only as prescribed relies on participant self-classification. The proposed 9-item Prescription CUD framework has not yet been validated against clinical outcomes or adopted by DSM-5 itself. What This Paper Does Not Show This study does not show that medical cannabis is free of dependence risk, that tolerance and withdrawal never matter clinically, or that no patient using cannabis as prescribed can develop a substance use disorder. It does not validate the Prescription CUD framework as a new official diagnosis, and it does not establish how these findings would translate to prescribing systems outside Australia. How This Fits With the Broader Clinical Conversation Every major cannabinoid receptor pathway can produce tolerance with regular dosing, which is why prescribers of opioids, benzodiazepines, and other controlled substances already distinguish physical dependence from a substance use disorder in clinical documentation. As more jurisdictions move toward prescription-based medical cannabis models, diagnostic tools originally built around unregulated, illicit use are being applied to a clinically different population, and this study is part of a growing effort to test whether that translation holds up. Dr. Caplan’s Take *This finding matches what many of us who prescribe medical cannabis see in practice. A patient who has titrated to a stable, effective dose and experiences mild tolerance or a few days of disrupted sleep if they miss doses is showing expected pharmacology, not loss of control over their use.* *That said, this is one survey from one country, and it should not be read as permission to stop screening prescribed patients for genuine problematic use. The right response is to keep asking about function, cravings, and unsuccessful attempts to cut down, the criteria that actually distinguish a use disorder from expected physiologic adaptation, rather than assuming every prescribed patient with tolerance has a diagnosable condition, or dismissing every prescribed patient’s use as automatically safe.* What a Careful Reader Should Take Away If you prescribe or manage medical cannabis patients, consider whether tolerance and withdrawal are doing appropriate diagnostic work in your documentation, and continue to screen for the criteria that actually indicate loss of control, such as unsuccessful attempts to cut down, cravings, and use despite functional harm. Evidence Interpretation Guide ## How to Read a Diagnostic Framework Comparison Study This study did not test a treatment. It tested two different ways of counting the same survey responses to see how diagnostic definitions change apparent disease prevalence. That distinction matters because the result here is a measurement question, not a treatment effect question. ### Four Questions for Interpreting the Findings **What Was Actually Compared?**Two scoring systems applied to the same 2,054 respondents, not two different patient populations or a treatment versus placebo. **Who Was Included?**Australian adults who self-reported prescribed medical cannabis use in the past year through an anonymous online survey, not a clinically verified or randomly sampled population. **What Changed, and What Did Not?**The proposed criteria changed which respondents met a Cannabis Use Disorder threshold. It did not change how much cannabis anyone used or their underlying clinical status. **What Would Confirm This Finding?**Replication in other countries and prescribing systems, and validation of the Prescription CUD framework against independent clinical outcomes rather than self-report alone. The Research Question Does removing tolerance and withdrawal from Cannabis Use Disorder criteria change apparent disorder prevalence among patients using medical cannabis exactly as prescribed? The Practical Question Does this study mean I don’t have Cannabis Use Disorder if my doctor prescribed my cannabis? The Bottom Line No. It means the standard diagnostic criteria used for cannabis use disorder may need refinement for prescribed patients, not that a prescription rules out a use disorder. Talk with your prescriber about your specific pattern of use. CED Perspective Lens ## The Same Study Can Mean Different Things Depending on the Question Being Asked Scientific papers rarely answer a single question. Patients, clinicians, researchers, policymakers, and critics often read the same data differently. The perspectives below explore how this study looks through several evidence-based lenses. Lens Overview This study affects patients, prescribers, insurers, employers, and researchers differently. These perspectives separate the diagnostic-framework question from individual clinical judgment. #### A Prescription Does Not Automatically Mean or Rule Out a Use Disorder If you use medical cannabis exactly as prescribed and notice you need more to get the same effect, or feel different if you miss a dose, that alone does not mean you have a use disorder under this proposed framework. It is still worth discussing openly with your prescriber, since only a clinician who knows your full picture can tell whether your pattern of use reflects expected tolerance or something that needs a closer look. Lens takeaway Discuss tolerance and dosing changes with your prescriber rather than assuming either extreme. #### Consider Whether Tolerance and Withdrawal Are Doing Fair Diagnostic Work For patients using cannabis strictly as prescribed, tolerance and withdrawal may reflect expected pharmacology rather than loss of control, similar to how these criteria are already interpreted for other prescribed controlled substances. This does not mean abandoning screening. Criteria like unsuccessful attempts to cut down, craving, and continued use despite functional harm remain informative regardless of prescription status. Lens takeaway Weight tolerance and withdrawal carefully when a patient is adherent to a legitimate prescription. #### Physical Dependence Is Not the Same as Addiction Family members may worry when they see a loved one needing a higher cannabis dose over time or feeling unwell without it. This study is a reminder that tolerance and withdrawal are common with many prescribed medications and are not, by themselves, proof of addiction. Lens takeaway Ask about function and control, not just dose changes, when assessing a loved one’s use. #### One Country, One Survey, One Proposed Framework This is a single cross-sectional, self-reported survey from Australia, and the Prescription CUD framework it tests has not been independently validated or adopted into diagnostic manuals. Self-classification of using only as prescribed cannot be verified against pharmacy records within this design, which leaves room for misclassification in either direction. Lens takeaway Treat the specific prevalence numbers as framework-dependent estimates, not confirmed diagnostic rates. #### Diagnostic Definitions Have Real Consequences A Cannabis Use Disorder diagnosis can affect insurance coverage, employment, custody proceedings, and legal outcomes, so how these criteria are defined is not a purely academic question. The authors argue that policy and insurance systems should account for the difference between prescribed, monitored cannabis use and unregulated illicit use when applying diagnostic labels. Lens takeaway Diagnostic framework choices carry downstream legal and financial consequences for prescribed patients. #### A Within-Sample Comparison, Not a New Population Study By applying two scoring frameworks to the same respondents, the authors isolated the specific effect of removing tolerance and withdrawal criteria, which is methodologically useful. The next step for this research is external validation: does the Prescription CUD framework track meaningfully with functional outcomes, treatment-seeking, or clinician-rated severity, not just self-reported symptom counts. Lens takeaway The design isolates a scoring effect; it does not yet validate a new clinical outcome. #### Echoes a Long-Standing Debate in Prescribed Controlled Substances Addiction medicine has long distinguished physical dependence from substance use disorder for opioids and benzodiazepines prescribed appropriately for pain, anxiety, or other indications. This study extends that same clinical logic to medical cannabis, arguing that a prescription-aware diagnostic lens may reduce misclassification without eliminating the need for careful screening. Lens takeaway The tolerance-versus-disorder distinction is not new to medicine, only newly applied to cannabis. #### Validation Against Outcomes Is the Next Step Future work should test whether the Prescription CUD framework predicts real clinical outcomes, such as treatment-seeking, functional impairment, or dose escalation beyond prescribed parameters, better than standard DSM-5 criteria. Studies outside Australia, in prescribing systems such as the United States, will also be needed before any framework change could be broadly adopted. Lens takeaway The next evidence phase should link diagnostic framework to real-world clinical outcomes. Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion](https://cedclinic.com/interact/discussion-forums/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Share this Evidence Watch [X](https://twitter.com/intent/tweet?text=Are+We+Over-Diagnosing+Cannabis+Use+Disorder+in+Prescribed+Medical+Cannabis+Patients%3F&url=https%3A%2F%2Fcedclinic.com%2Fprescription-cannabis-use-disorder-dsm5-study%2F) [LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2Fprescription-cannabis-use-disorder-dsm5-study%2F) [BlueSky](https://bsky.app/intent/compose?text=Are+We+Over-Diagnosing+Cannabis+Use+Disorder+in+Prescribed+Medical+Cannabis+Patients%3F%20https%3A%2F%2Fcedclinic.com%2Fprescription-cannabis-use-disorder-dsm5-study%2F) [Instagram](https://www.instagram.com/drcaplan/) [Substack](https://doctorapprovedcannabis.substack.com/) [RSS](https://cedclinic.com/feed/) Source: [Cannabis use disorder in patients prescribed medical cannabis-Should we consider prescription cannabis use disorder as a new diagnostic condition?](https://pubmed.ncbi.nlm.nih.gov/42543176/) Related Reading at CED Clinic Continue exploring the evidence [SAMHSA’s 2026 Clinical Guidance for Physicians and Patients on Cannabis Use Disorder](https://cedclinic.com/medical-marijuana-vs-cannabis-use-disorder-samhsa-2026/) Federal guidance instructing physicians to evaluate cannabis use by clinical signs of harm rather than use alone. [Read the SAMHSA guidance breakdown](https://cedclinic.com/medical-marijuana-vs-cannabis-use-disorder-samhsa-2026/) [UK Medical Cannabis Use: What a New National Survey Found](https://cedclinic.com/uk-medical-cannabis-prescriptions-high-risk-use/) A national survey on prescribed medical cannabis users and high-risk use screening. [Read the UK survey findings](https://cedclinic.com/uk-medical-cannabis-prescriptions-high-risk-use/) [Medical vs. Recreational Cannabis Use: Survey Reveals Overlap](https://cedclinic.com/cannabis-use-psychiatric-symptoms-overlap-survey/) Survey data on the overlap between medical and recreational cannabis use patterns. [Read the overlap survey](https://cedclinic.com/cannabis-use-psychiatric-symptoms-overlap-survey/) Similar Studies on CEDClinic.com Earlier coverage on closely related evidence When a new paper overlaps with earlier CED Clinic coverage, we preserve the chain instead of hiding the overlap. These links point to older related posts so readers can compare what is new, what is repeated, and how the evidence has moved. Related digest item [GLP-1 and Cannabis Use Disorder: The BMJ Study Explained](https://cedclinic.com/glp-1-cannabis-use-disorder-bmj-cohort-study/) A BMJ cohort study of 606,434 veterans found GLP-1 drugs reduced cannabis use disorder risk by 14 percent. Related Cannabis Use Disorder topic, but a different study population and research question (medication effect on CUD risk, not diagnostic criteria). [Compare earlier coverage](https://cedclinic.com/glp-1-cannabis-use-disorder-bmj-cohort-study/) Related digest item [SAMHSA’s 2026 Clinical Guidance for Physicians and Patients on Cannabis Use Disorder](https://cedclinic.com/medical-marijuana-vs-cannabis-use-disorder-samhsa-2026/) SAMHSA’s 2026 advisory instructs physicians to evaluate cannabis use based on clinical signs of harm, not use alone. Related diagnostic-philosophy topic, but a federal guidance summary rather than this new primary-data study. [Compare earlier coverage](https://cedclinic.com/medical-marijuana-vs-cannabis-use-disorder-samhsa-2026/) Related digest item [Medical vs. Recreational Cannabis Use: Survey Reveals Overlap](https://cedclinic.com/cannabis-use-psychiatric-symptoms-overlap-survey/) A survey of cannabis users found significant overlap between medical and recreational use patterns. Related medical-versus-recreational use theme, but does not test diagnostic criteria frameworks. [Compare earlier coverage](https://cedclinic.com/cannabis-use-psychiatric-symptoms-overlap-survey/) ## Frequently Asked Questions What did this study examine? It examined whether removing tolerance and withdrawal from standard DSM-5 Cannabis Use Disorder criteria changes apparent disorder prevalence among 2,054 Australian adults prescribed medical cannabis. What is Prescription Cannabis Use Disorder? It is a proposed 9-item diagnostic framework that uses the same DSM-5 criteria as standard Cannabis Use Disorder but excludes tolerance and withdrawal, intended for patients using cannabis strictly as prescribed. How much did the diagnosis rate change? Among the 986 patients using cannabis only as prescribed, any Cannabis Use Disorder fell from 20 percent under standard 11-item DSM-5 criteria to 9 percent under the 9-item Prescription CUD framework. What about more severe disorder? Moderate-to-severe Cannabis Use Disorder in the same as-prescribed subgroup fell from 5 percent to 2 percent using the prescription-aware framework. Where and when was this published? The study was published in the journal Addiction on August 2, 2026, with PMID 42543176 and DOI 10.1111/add.70559. Who conducted the study? Researchers Nicholas Lintzeris and Llewellyn Mills, affiliated with the University of Sydney and South Eastern Sydney Local Health District in Australia, using data from the CAMS22 survey. Does this mean tolerance never matters clinically? No. Tolerance and withdrawal can still be clinically important. The study argues they should be weighed differently when a patient is using cannabis strictly as prescribed rather than automatically counted as disorder criteria. Is the Prescription CUD framework an official diagnosis? Not yet. It is a proposed research framework and has not been adopted into DSM-5 or validated against independent clinical outcomes. What are the main limitations? The study relies on a single, self-reported, anonymous cross-sectional survey from Australia, so findings may not generalize to other countries or prescribing systems, and using only as prescribed could not be independently verified. What should patients using prescribed medical cannabis take from this? A prescription does not automatically confirm or rule out a use disorder. Patients should discuss any changes in tolerance, dose, or perceived need for cannabis openly with their prescriber.   ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).